Publisher
Springer Science and Business Media LLC
Reference5 articles.
1. Genovese MC, Kremer J, Zamani O, Ludivico C, Krogulec M, Xie L et al (2016) Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med 374:1243–1252
2. Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, et al. (2020) Baricitinib plus remdesivir for hospitalized adults with covid-19. N Engl J Med [Internet] 2020 [cited 2021 Jul 4]; Available from: https://www.nejm.org/doi/https://doi.org/10.1056/NEJMoa2031994
3. Holtzman NG, Im A, Ostojic A, Curtis LM, Parsons-Wandell L, Nashed J et al (2020) Efficacy and safety of baricitinib in refractory chronic graft-versus-host disease (cGVHD): preliminary analysis results of a phase 1/2 study. Blood 136:1–1
4. Lu X, Tang LV, Wang H-F, You Y, Wang Y-D, Hu Y et al (2021) The great challenge of managing recipients of hematopoietic stem cell transplantation combined with COVID-19. Bone Marrow Transplant 56:696–700
5. Information NC for B, Pike USNL of M 8600 R, MD B, Usa 20894. Cost Comparison [Internet]. Canadian Agency for Drugs and Technologies in Health; 2019 [cited 2021 Jul 14]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK549721/Table
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献